Relationship Between Interleukin-6 −174G/C Genetic Variant and Efficacy of Methotrexate Treatment in Psoriatic Arthritis Patients

References

• Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;64:37–39. doi:10.1136/ard.2004.030775
   Web of Science ®Google Scholar
• Dernis E, Lavie F, Salliot C, et al. Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion. Joint Bone Spine. 2009;76(5):524–531. doi:10.1016/j.jbspin.2009.03.002
   Web of Science ®Google Scholar
• Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387–1394. doi:10.1136/ard.2008.094946
   PubMed Web of Science ®Google Scholar
• Kraan MC, Smeets TJ, van Loon MJ, et al. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis. 2004;63:1056–1061. doi:10.1136/ard.2003.014738
   PubMed Web of Science ®Google Scholar
• Straub RH, Müller-Ladner U, Lichtinger T, et al. Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. Br J Rheumatol. 1997;36:1298–1303. doi:10.1093/rheumatology/36.12.1298
   PubMedGoogle Scholar
• Assier E, Boissier MC, Dayer JM. Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine. 2010;77:532–536. doi:10.1016/j.jbspin.2010.07.007
   PubMed Web of Science ®Google Scholar
• Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265(3):621–636. doi:10.1042/bj2650621
   PubMed Web of Science ®Google Scholar
• Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol. 2003;24(1):25–29. doi:10.1016/S1471-4906(02)00013-3
   PubMed Web of Science ®Google Scholar
• Kotake S, Sato K, Kim KJ, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996;11:88–95. doi:10.1002/jbmr.5650110113
   PubMed Web of Science ®Google Scholar
• Le Goff B, Blanchard F, Berthelot JM, Heymann D, Maugars Y. Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine. 2010;77:201–205. doi:10.1016/j.jbspin.2010.03.002
   PubMed Web of Science ®Google Scholar
• Scheller J, Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol. 2006;195(4):173–183. doi:10.1007/s00430-006-0019-9
   PubMed Web of Science ®Google Scholar
• Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102(7):1369–1376. doi:10.1172/JCI2629
   PubMed Web of Science ®Google Scholar
• Galicia JC, Tai H, Komatsu Y, et al. Polymorphisms in the IL-6 Receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun. 2004;5(6):513–516. doi:10.1038/sj.gene.6364120
   Web of Science ®Google Scholar
• Ferreira RC, Freitag DF, Cutler AJ, et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLoS Genet. 2013;9(4):e1003444. doi:10.1371/journal.pgen.1003444
   PubMed Web of Science ®Google Scholar
• IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379(9822):1205–1213. doi:10.1016/S0140-6736(11)61931-4
   Web of Science ®Google Scholar
• Revez JA, Bain L, Chapman B, et al. A new regulatory variant in the interleukin-6 receptor gene associates with asthma risk. Genes Immun. 2013;14(7):441–446. doi:10.1038/gene.2013.38
   PubMed Web of Science ®Google Scholar
• Wang Y, Hu H, Wu J, et al. The IL6R gene polymorphisms are associated with sIL-6R, IgE and lung function in Chinese patients with asthma. Gene. 2016;585(1):51–57. doi:10.1016/j.gene.2016.03.026
   Web of Science ®Google Scholar
• Reich D, Patterson N, Ramesh V, et al. Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet. 2007;80:16–726. doi:10.1086/513206
   Web of Science ®Google Scholar
• Schotte H, Schmidt H, Gaubitz M, et al. Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis. Clin Rheumatol. 2015;34(12):2021–2028. doi:10.1007/s10067-015-3107-7
   Web of Science ®Google Scholar
• Zavaleta-Muniz SA, Martin-Marquez BT, Gonzalez-Lopez L, et al. The −174G/C and −572G/C interleukin 6 promoter gene polymorphisms in mexican patients with rheumatoid arthritis: a Case-Control Study. Clin Dev Immunol. 2013;2013:959084. doi:10.1155/2013/959084
   PubMedGoogle Scholar
• Li F, Xu J, Zheng J, et al. Association between interleukin-6 gene polymorphisms and rheumatoid arthritis in Chinese han population: a case control study and a meta-analysis. Sci Rep. 2014;4:5714. doi:10.1038/srep05714
   PubMed Web of Science ®Google Scholar
• Ogilvie EM, Fife MS, Thompson SD, et al. The Ϫ174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multi- center study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum. 2003;48:3202–3206. doi:10.1002/art.11300
   PubMed Web of Science ®Google Scholar
• Pawlik A, Wrzesniewska J, Florczak M, et al. IL-6 promoter polymorphism in patients with rheumatoid arthritis. Scand J Rheumatol. 2005;34(2):109–113. doi:10.1080/03009740510026373
   PubMed Web of Science ®Google Scholar
• Wielińska J, Dratwa M, Świerkot J, et al. Interleukin 6 gene polymorphism is associated with protein serum level and disease activity in polish patients with rheumatoid arthritis. HLA. 2018;92:38–41. doi:10.1111/tan.13355
   Web of Science ®Google Scholar
• Ceccarelli F, Perricone C, Fabris M, et al. Transforming growth factor β 869C/T and interleukin 6-174G/C polymorphisms relate to the severity and progression of bone-erosive damage detected by ultrasound in rheumatoid arthritis. Arthritis Res Ther. 2011;13:R111. doi:10.1186/ar3396
   Web of Science ®Google Scholar
• Marinou I, Healy J, Mewar D, et al. Association of interleukin-6 and interleukin-10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody status. Arthritis Rheum. 2007;56(8):2549–2556. doi:10.1002/art.22814
   Web of Science ®Google Scholar
• Panoulas VF, Douglas KMJ, Smith JP, et al. Transforming growth factor-b1 869T/C, but not interleukin-6#174G/C, polymorphism associates with hypertension in rheumatoid arthritis. Rheumatology. 2009;48:113–118. doi:10.1093/rheumatology/ken443
   PubMed Web of Science ®Google Scholar
• Palomino-Morales R, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, et al. Interleukin-6 gene −174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2009;6:964–970.
   Google Scholar
• López-Mejías R, García-Bermúdez M, González-Juanatey C, et al. Lack of association between IL6 single nucleotide polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis. Atherosclerosis. 2011;219(2):655–658. doi:10.1016/j.atherosclerosis.2011.07.124
   Web of Science ®Google Scholar
• Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS, et al. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis. 2009;204(1):178–183. doi:10.1016/j.atherosclerosis.2008.08.036
   Web of Science ®Google Scholar
• Davila-Fajardo CL, Marquez A, Pascual-Salcedo D, et al. Confirmation of −174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. Pharmacogenet Genomics. 2014;24(1):1–5. doi:10.1097/FPC.0000000000000013
   Web of Science ®Google Scholar
• Jančić I, Šefik-Bukilica M, Živojinović S, et al. Influence of promoter polymorphisms of the TNF-α (−308G/A) and IL-6 (−174G/C) genes on therapeutic response to etanercept in rheumatoid arthritis. J Med Biochem. 2015;34(4):414–421. doi:10.2478/jomb-2014-0060
   PubMed Web of Science ®Google Scholar
• Pawlik A, Czerny B, Dabrowska-Zamojcin E, et al. The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone. Pol Arch Med Wewn. 2005;114(3):843–847.
   Google Scholar
• Ruiz-Padilla AJ, Gamez-Nava JI, Saldaña-Cruz AM, et al. The −174G/C interleukin-6 gene promoter polymorphism as a genetic marker of differences in therapeutic response to methotrexate and leflunomide in rheumatoid arthritis. Biomed Res Int. 2016;2016:1–10. doi:10.1155/2016/4193538
   Web of Science ®Google Scholar
• Fabris M, Quartuccio L, Lombardi S, et al. The CC homozygosis of the −174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun Rev. 2012;11:315–320. doi:10.1016/j.autrev.2010.06.012
   PubMed Web of Science ®Google Scholar
• Cubino N, Montilla C, Usategui-Martín R, et al. Association of IL1Β (−511 A/C) and IL6 (−174 G > C) polymorphisms with higher disease activity and clinical pattern of psoriatic arthritis. Clin Rheumatol. 2016;35(7):1789–1794. doi:10.1007/s10067-016-3301-2
   PubMed Web of Science ®Google Scholar
• Balding J, Kane D, Livingstone W, et al. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum. 2003;48(5):1408–1413. doi:10.1002/art.10935
   Web of Science ®Google Scholar
• Białecka M, Ostasz R, Kurzawski M, et al. IL6−174G>C polymorphism is associated with an increased risk of psoriasis but not response to treatment. Exp Dermatol. 2015;24(2):146–147. doi:10.1111/exd.12577
   Web of Science ®Google Scholar
• Di Renzo L, Bianchi A, Saraceno R, et al. −174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers. Pharmacogenet Genomics. 2012;22(2):134–142. doi:10.1097/FPC.0b013e32834e5e7b
   Web of Science ®Google Scholar
• Baran W, Szepietowski JC, Mazur G, Baran E. IL-6 and IL-10 promoter gene polymorphisms in psoriasis vulgaris. Acta Derm Venereol. 2008;88(2):113–116. doi:10.2340/00015555-0427
   Web of Science ®Google Scholar
• Boca AN, Talamonti M, Galluzzo M, et al. Genetic variations in IL6 and IL12B decreasing the risk for psoriasis. Immunol Lett. 2013;156(1–2):127–131. doi:10.1016/j.imlet.2013.09.028
   Web of Science ®Google Scholar
• Enevold C, Baslund B, Linde L, et al. Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis. Pharmacogenet Genomics. 2014;24(8):401–405. doi:10.1097/FPC.0000000000000071
   Web of Science ®Google Scholar
• Hassan B, Maxwell JR, Hyrich KL, et al. Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. Rheumatology. 2010;49(1):43–47. doi:10.1093/rheumatology/kep372
   Web of Science ®Google Scholar
• Maldonado-Montoro M, Cañadas-Garre M, González-Utrilla A, et al. Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis. Pharm J. 2018;18:167–172.
   Google Scholar
• Ibrahim I, McAllister K, Plant D, et al. Investigation of an interleukin-6 receptor gene polymorphism (rs2228145) as a predictor of cardiovascular mortality in inflammatory polyarthritis: results from the Norfolk Arthritis Register: table 1. Ann Rheum Dis. 2014;73(4):787–788. doi:10.1136/annrheumdis-2013-204330
   Web of Science ®Google Scholar
• Marinou I, Walters K, Winfield J, et al. A gain of function polymorphism in the interleukin 6 receptor influences RA susceptibility. Ann Rheum Dis. 2010;69(6):1191–1194. doi:10.1136/ard.2008.100644
   Web of Science ®Google Scholar
• Lamas JR, Rodríguez-Rodríguez L, Varadé J, et al. Influence of IL6R rs8192284 polymorphism status in disease activity in rheumatoid arthritis. J Rheumatol. 2010;37(8):1579–1581. doi:10.3899/jrheum.091455
   Web of Science ®Google Scholar
• Cénit MC, Simeón CP, Fonollosa V, et al. No evidence of association between functional polymorphisms located within IL6R and IL6ST genes and systemic sclerosis. Tissue Antigens. 2012;80(3):254–258. doi:10.1111/j.1399-0039.2012.01915.x
   Google Scholar
• Esparza-Gordillo J, Schaarschmidt H, Liang L, et al. A functional IL-6 receptor (IL6R) variant is a risk factor for persistent atopic dermatitis. J Allergy Clin Immunol. 2013;132(2):371–377. doi:10.1016/j.jaci.2013.01.057
   Web of Science ®Google Scholar
• Goupille P. Psoriatic arthritis. Joint Bone Spine. 2005;72(6):466–470. doi:10.1016/j.jbspin.2005.10.006
   Web of Science ®Google Scholar
• Fransen J, Antoni C, Mease PJ, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis. 2006;65:1373–1378. doi:10.1136/ard.2006.051706
   PubMed Web of Science ®Google Scholar
• Mease PJ, Antoni CE, Gladman DD, et al. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis. 2005;64 Suppl 2(Suppl 2):ii49–ii54. doi:10.1136/ard.2004.034165
   Web of Science ®Google Scholar
• Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res. 2009;37(suppl_2):W600–W605. doi:10.1093/nar/gkp290
   Web of Science ®Google Scholar
• Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature. 2015;526:68–74.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2016. Available from: http://www.R-project.org/. Accessed December 23, 2020.
   Google Scholar
• Nowell MA, Richards PJ, Horiuchi S, et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol. 2003;171(6):3202–3209. doi:10.4049/jimmunol.171.6.3202
   PubMed Web of Science ®Google Scholar
• Sasai M, Saeki Y, Ohshima S, et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 1999;42(8):1635–1643. doi:10.1002/1529-0131(199908)42:8<1635::AID-ANR11>3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar
• Takagi N, Mihara M, Moriya Y, et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 1998;41:2117–2121. doi:10.1002/1529-0131(199812)41:12<2117::AID-ART6>3.0.CO;2-P
   PubMed Web of Science ®Google Scholar
• Lee YH, Lee HS, Choi SJ, et al. The association between interleukin-6 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus. 2012;21(1):60–67. doi:10.1177/0961203311422711
   Web of Science ®Google Scholar
• Illig T, Bongardt F, Schopfer A, et al. Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes. J Clin Endocrinol Metab. 2004;89:5053–5058. doi:10.1210/jc.2004-0355
   PubMed Web of Science ®Google Scholar
• Vozarova B, Fernandez-Real JM, Knowler WC, et al. The interleukin-6 (−174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in native Americans and Caucasians. Hum Genet. 2003;112:409–413.
   PubMed Web of Science ®Google Scholar
• Sfrent-Cornateanu R, Mihai C, Balan S, et al. The IL - 6 promoter polymorphism is associated with disease activity and disability in systemic sclerosis. J Cell Mol Med. 2006;10(4):955–959. doi:10.1111/j.1582-4934.2006.tb00538.x
   Web of Science ®Google Scholar
• Xu W-D, Zhou M, Peng H, et al. Lack of association of IL-6 polymorphism with rheumatoid arthritis/type 1 diabetes: a meta-analysis. Joint Bone Spine. 2013;80(5):477–481. doi:10.1016/j.jbspin.2012.11.005
   Web of Science ®Google Scholar